Abstract Library

#3257 Molecular and functional study of somatostatin receptors in pheochromocytomas and paragangliomas

Introduction: Most pheochromocytomas (PCC) and paragangliomas (PGL) are benign neuroendocrine tumors that overproduce catecholamines causing hypertension, arrhythmia, and stroke; however, 10 30% may present distant metastasis. About 40% are caused by germline mutations, which may be classified in 3 different clusters. PCC/PGL diagnosis involves blood/urine tests and imaging techniques, while their treatment often requires distinct pharmacological and surgical approaches. Thus, identification of new biomarkers for early diagnosis, and progression/response would help to avoid unnecessary tests and enable personalized medicine approaches.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ibáñez-Costa A

Authors: Ibáñez-Costa A, Blázquez-Encinas R, Alors-Pérez E, Fuentes-Fayos A, Rivero-Cortés E,

Keywords: pheochromocytoma, paraganglioma, somatostatin, somatostatin receptor, neuroendocrine tumor,

#1707 Implication of Neuropilin-2 in the Progression of Small Intestinal Neuroendocrine Tumors: Towards a Promising Therapeutic Target?

Introduction: Small intestinal neuroendocrine tumors (siNETs) are rare tumors that raise several clinical and therapeutic challenges. Current treatments are not efficient, in part because of a poor understanding of their mechanisms of progression. We recently highlighted some axon guidance molecules (AGMs) that might be implicated in the progression of siNETs. Among them, we are currently focusing our efforts on the semaphorin 3F receptor neuropilin-2 (NRP2).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Bollard J, Massoma P, Patte C, Carbonnaux M, Vercherat C,

Keywords: siNETs, progression, NRP2 ,

#1166 mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis

Introduction: Pancreatic neuroendocrine tumors (pNETs) are generally chemoresistants probably due to low proliferation rate and defects in apoptotic pathway. Targeted therapies are new encouraging options for pNETs however; clinical trials show limited objective response. Combination of chemotherapy and targeted therapy could be a new solution in therapeutic care. Streptozotocin (STZ) is the 1st line of therapy for unresectable pNETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Vercherat C

Authors: Vercherat C, Walter T, Massoma-Peh P, Bollard J, Lacheretz-Bernigaud A,

Keywords: neuroendocrine, therapy, Streptozotocin, mTOR pathway, combination, pre-clinical study,

#604 Expression of Netrin-1 and its Receptors in pNETs

Introduction: Netrin-1, a member of axon guidance molecules, and its dependence receptors (DCC, UNC5, neogenin) is involved in several cancer types (breast, neuroblastoma, colon etc) but its role in pNETs remains unknown.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Benslama N, Bollard J, Massoma P, Vercherat C, Hervieu V,

Keywords: netrin-1, pNET, progression,

#603 Role of Semaphorins and Their Signaling Pathway in the Progression of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: Semaphorin family, a part of axon guidance molecules, is involved in many types of epithelial cancers. However, little is known about its potential function in GEP-NETs.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Bollard J, Massoma P, Blanc M, Vercherat C, Lepinasse F,

Keywords: semaphorins, progression, biomarker,